Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lower rate of gout than those prescribed a GLP1 agonist. Sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout among adults with type 2 diabetes mellitus, although future studies are necessary to confirm this observation (Annals of Internal Medicine)
Diabetes News
Tag: Type 2 Diabetes
Five‐year effectiveness of bariatric surgery on disease remission, weight loss, and changes of metabolic parameters in obese patients with type 2 diabetes
Bariatric surgery was effective in weight loss, remission of diabetes, and dyslipidaemia in 5‐year post‐surgery (Diabetes/Metabolism Research and Reviews)
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
In SUSTAIN and PIONEER combined, glucagon‐like peptide‐1 analogue semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF (Diabetes, Obesity and Metabolism)
Ethnic Differences in the Prevalence of Type 2 Diabetes Diagnoses in the UK: Cross-Sectional Analysis of the Health Improvement Network Primary Care Database
The prevalence of type 2 diabetes was higher in the Asian and Black ethnic groups, compared with the White group. Accurate estimates of ethnic prevalence of type 2 diabetes based on large datasets are important for facilitating appropriate allocation of public health resources, and for allowing population-level research to be undertaken examining disease trajectories among minority ethnic groups, that might help reduce inequalities (Clinical Epidemiology)
12‐Year Trends in Pharmacologic Treatment of Type 2 Diabetes among Patients with Heart Failure in the United States
Despite their promising cardiovascular safety profile, SGLT‐2i use remains relatively limited (Diabetes, Obesity and Metabolism)
Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin‐Naïve Patients with Type 2 Diabetes after Failure of Oral Therapy in a Real World Setting
Starting a BOT regimen with Gla‐300 allowed about 60% of 721 German and Swiss patients with inadequately controlled type 2 diabetes to achieve glycaemic control within 12 months in daily clinical practice. Glycaemic control was achieved without weight gain or increased risk of nocturnal or severe hypoglycaemia (Diabetes, Obesity and Metabolism)
Effect of mean HbA1c on the association of HbA1c variability and all‐cause mortality in patients with type 2 diabetes mellitus
Mean HbA1c contributed to the correlation between HbA1c variability and all‐cause mortality. The risks associated with HbA1c variability and glycemic control status were similar. The relationship between mean HbA1c and mortality presented a J‐shaped distribution for both low and high HbA1c variability (Diabetes, Obesity and Metabolism)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018
A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetologia)
Plasma Lipidome and Prediction of Type 2 Diabetes in the Population-Based Malmö Diet and Cancer Cohort
A lifestyle-related lipidomic profile strongly predicts T2DM development beyond current risk factors. Further studies are warranted to test if lifestyle interventions modifying this lipidomic profile can prevent T2DM (Diabetes Care)
Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes
Our study suggests that metformin use at the time of first AMI is associated with increased risk of cardiovascular disease and death in patients with T2DM, while its use post-AMI might be beneficial (Cardiovascular Diabetology)
Persistent whole day meal effects of three dipeptidyl peptidase‐4 inhibitors on glycemia and hormonal responses in metformin‐treated type 2 diabetes
DPP‐4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP‐4 inhibitors (Diabetes, Obesity and Metabolism)
Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK
A cohort study using primary care data from the United Kingdom (Primary Care Diabetes)
Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
Sustained reductions in glycaemia and related cardiovascular risk factors over 10 years among people with screen-detected diabetes managed in primary care are achievable. The differences in prescribed treatment and cardiovascular risk factors in the 5 years following diagnosis were not maintained at 10 years, and the difference in cardiovascular events and mortality remained non-significant (The Lancet Diabetes & Endocrinology)
Effectiveness of self‐management interventions in young adults with type 1 and 2 diabetes: a systematic review and meta‐analysis
Current self‐management interventions did not improve outcomes in young adults with diabetes. Our findings, which contrast with those from systematic reviews in older adults, highlight the need for the development of more effective interventions for young adults with diabetes (Diabetic Medicine)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
These results suggest that liraglutide treatment is associated with reduced total MACE compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events. This analysis supports the findings of an absolute benefit of liraglutide treatment with respect to the overall burden of cardiovascular events in this high-risk patient population (JAMA Cardiology)
Sleep and HbA1c in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most?
Sleep in general may be a modifiable factor of importance for patients with T2D. The prevention of sleep curtailment may serve as a primary focus in the sleep-centered management of T2D (Diabetes Care)
Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
Our findings suggest that disparity in glycaemic control, diabetes-related monitoring, and prescription of newer therapies remains a challenge in diabetes care. Both SES and ethnicity were important determinants of inequality. Disparities in glycaemic control and other areas of care may lead to higher rates of complications and adverse outcomes for some groups (PLOS Medicine)
Factors Mediating Type 2 Diabetes Remission and Relapse after Gastric Bypass Surgery
This longitudinal retrospective analysis shows that preoperative insulin use and age, one-year weight loss, and regain after that influence T2D remission and relapse following RYGB. Referring patients at a younger age, before insulin is needed, and optimizing both weight loss and weight maintenance after RYGB may improve the rates and durability of T2D remission (Journal of the American College of Surgeons)
Appropriateness of action prompts for hypoglycaemia and hyperglycaemia in type 2 diabetes self‐management apps
Less than one‐fifth of apps provided evidence‐based steps to guide patients through hypo‐ and hyperglycaemia. The majority of apps failed to provide just‐in‐time diabetes self‐management education to prevent frequent or severe episodes of hypo‐ and hyperglycaemia (Diabetes/Metabolism Research and Reviews)
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Delivering evidence based, patient centered care to people with type 2 diabetes requires a paradigm shift and departure from the predominantly glucocentric view of diabetes management. Instead of prioritizing intensive glycemic control, the focus needs to be on ensuring access to adequate diabetes care (BMJ)
- 1
- 2
- 3
- …
- 42
- Next Page »
Glycosmedia is also available as an App: